News & Views
Biohit Agrees Distribution Deal for ELISA Test
May 11 2016
Tianjin Jingsheng Biological Technology Development Co. Ltd has become a distributor in China for Biohit Oyj’s Calprotectin ELISA test. The test provides quick means of measuring calprotectin in a stool sample and differentiates inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) ; it is also useful for monitoring of treatment in IBD patients.
General Director Zeng Zhao Hong, Tianjin Jingsheng Biological Technology Development Co. Ltd said: “In China there seems to be differences in prevalence of IBD between rural and urban population. The disease is increasing particularly among young people. Fecal calprotectin is an emerging biomarker of gut inflammation. Biohit Calprotectin test differentiates reliably IBD and IBS and reduces significantly the need of colonoscopies.”
CEO Semi Korpela, Biohit Oyj: “We are starting a co-operation with Tianjin Jingsheng Biological Technology Development Co. Ltd in the large Chinese market. We have started the registration in China required to obtain the marketing authorisation for the product.”
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK